Swissmedic approves Norgine's Ifinwil for children diagnosed with high─risk neuroblastoma
Norgine, a leading European specialty pharmaceutical company, announced that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy for the treatment of paediatric patients from one year with high-risk neuroblastoma (HRNB). “This …